145 related articles for article (PubMed ID: 36290812)
21. [Venetoclax with low-dose cytarabine for patients with untreated acute myeloid leukemia ineligible for intensive chemotherapy: results from the Chinese cohort of a phase three randomized placebo-controlled trial].
Hu Y; Jin J; Zhang Y; Hu JD; Li JM; Wei XD; Gao SJ; Zha JH; Jiang Q; Wu J; Mendes W; Wei AH; Wang JX
Zhonghua Xue Ye Xue Za Zhi; 2021 Apr; 42(4):288-294. PubMed ID: 33979972
[No Abstract] [Full Text] [Related]
22. Real-world treatment patterns and healthcare resource use in patients with acute myeloid leukemia in Western Europe.
Kabra M; Margotto L; Manuguid F
Future Oncol; 2021 Jul; 17(21):2769-2784. PubMed ID: 33881356
[TBL] [Abstract][Full Text] [Related]
23. Patterns of undertreatment among patients with acute myeloid leukemia (AML): considerations for patients eligible for non-intensive chemotherapy (NIC).
Hubscher E; Sikirica S; Bell T; Brown A; Welch V; Russell-Smith A; D'Amico P
J Cancer Res Clin Oncol; 2021 Nov; 147(11):3359-3368. PubMed ID: 34462785
[TBL] [Abstract][Full Text] [Related]
24. Medicare fee-for-service enrollees with primary acute myeloid leukemia: an analysis of treatment patterns, survival, and healthcare resource utilization and costs.
Meyers J; Yu Y; Kaye JA; Davis KL
Appl Health Econ Health Policy; 2013 Jun; 11(3):275-86. PubMed ID: 23677706
[TBL] [Abstract][Full Text] [Related]
25. Cladribine and low-dose cytarabine alternating with decitabine as front-line therapy for elderly patients with acute myeloid leukaemia: a phase 2 single-arm trial.
Kadia TM; Cortes J; Ravandi F; Jabbour E; Konopleva M; Benton CB; Burger J; Sasaki K; Borthakur G; DiNardo CD; Pemmaraju N; Daver N; Ferrajoli A; Wang X; Patel K; Jorgensen JL; Wang S; O'Brien S; Pierce S; Tuttle C; Estrov Z; Verstovsek S; Garcia-Manero G; Kantarjian H
Lancet Haematol; 2018 Sep; 5(9):e411-e421. PubMed ID: 30115541
[TBL] [Abstract][Full Text] [Related]
26. Economic analysis of blood product transfusions according to the treatment of acute myeloid leukemia in the elderly.
Cannas G; Fattoum J; Boukhit M; Thomas X
Transfus Clin Biol; 2015; 22(5-6):341-7. PubMed ID: 26184429
[TBL] [Abstract][Full Text] [Related]
27. Venetoclax combinations induce high response rates in newly diagnosed acute myeloid leukemia patients ineligible for intensive chemotherapy in routine practice.
Apel A; Moshe Y; Ofran Y; Gural A; Wolach O; Ganzel C; Canaani J; Zektser M; Duek A; Stemer G; Hellman I; Basood M; Frisch A; Leibovitch C; Koren-Michowitz M
Am J Hematol; 2021 Jul; 96(7):790-795. PubMed ID: 33836555
[TBL] [Abstract][Full Text] [Related]
28. Outcomes and health care utilization of older patients with acute myeloid leukemia.
Sharplin K; Wee LYA; Singhal D; Edwards S; Danner S; Lewis I; Thomas D; Wei A; Yong ASM; Hiwase DK
J Geriatr Oncol; 2021 Mar; 12(2):243-249. PubMed ID: 32713804
[TBL] [Abstract][Full Text] [Related]
29. Costs per patient achieving remission with venetoclax-based combinations in newly diagnosed patients with acute myeloid leukemia ineligible for intensive induction chemotherapy.
Choi M; Song J; Bui CN; Ma E; Chai X; Yin L; Betts KA; Kapustyan T; Montez M; LeBlanc TW
J Manag Care Spec Pharm; 2022 Sep; 28(9):980-988. PubMed ID: 35708343
[No Abstract] [Full Text] [Related]
30. Venetoclax-based combinations for the treatment of newly diagnosed acute myeloid leukemia.
Othman TA; Azenkot T; Moskoff BN; Tenold ME; Jonas BA
Future Oncol; 2021 Aug; 17(23):2989-3005. PubMed ID: 34024158
[TBL] [Abstract][Full Text] [Related]
31. Treatment Pattern, Financial Burden, and Outcomes in Elderly Patients with Acute Myeloid Leukemia in Korea: A Nationwide Cohort Study.
Ha H; Jeong Y; Lim JH; Suh YJ
Int J Environ Res Public Health; 2022 Feb; 19(4):. PubMed ID: 35206499
[TBL] [Abstract][Full Text] [Related]
32. Clinical benefit of glasdegib plus low-dose cytarabine in patients with de novo and secondary acute myeloid leukemia: long-term analysis of a phase II randomized trial.
Heuser M; Smith BD; Fiedler W; Sekeres MA; Montesinos P; Leber B; Merchant A; Papayannidis C; Pérez-Simón JA; Hoang CJ; O'Brien T; Ma WW; Zeremski M; O'Connell A; Chan G; Cortes JE
Ann Hematol; 2021 May; 100(5):1181-1194. PubMed ID: 33740113
[TBL] [Abstract][Full Text] [Related]
33. A quality-adjusted survival time without symptoms or toxicities analysis of glasdegib plus low-dose cytarabine versus low-dose cytarabine as initial therapy for acute myeloid leukemia in patients who are not considered candidates for intensive chemotherapy.
Solem CT; Bell TJ; Kwon Y; Cappelleri JC; Johnson C; Bhattacharyya H; Hoang CJ; Cortes JE
Cancer; 2020 Oct; 126(19):4315-4321. PubMed ID: 32697335
[TBL] [Abstract][Full Text] [Related]
34. Patient characteristics, treatment patterns, and mortality in elderly patients newly diagnosed with acute myeloid leukemia meeting ineligibility criteria for high intensity chemotherapy.
Li S; Ji Y; Peng Y; Kota V; Kim C
Leuk Lymphoma; 2022 Jan; 63(1):131-141. PubMed ID: 34643153
[TBL] [Abstract][Full Text] [Related]
35. Impact of induction chemotherapy with intermediate-dosed cytarabine and subsequent allogeneic stem cell transplantation on the outcome of high-risk acute myeloid leukemia.
Fleischmann M; Schnetzke U; Frietsch JJ; Sayer HG; Schrenk K; Hammersen J; Glaser A; Hilgendorf I; Hochhaus A; Scholl S
J Cancer Res Clin Oncol; 2022 Jun; 148(6):1481-1492. PubMed ID: 34297206
[TBL] [Abstract][Full Text] [Related]
36. Gemtuzumab Ozogamicin Versus Best Supportive Care in Older Patients With Newly Diagnosed Acute Myeloid Leukemia Unsuitable for Intensive Chemotherapy: Results of the Randomized Phase III EORTC-GIMEMA AML-19 Trial.
Amadori S; Suciu S; Selleslag D; Aversa F; Gaidano G; Musso M; Annino L; Venditti A; Voso MT; Mazzone C; Magro D; De Fabritiis P; Muus P; Alimena G; Mancini M; Hagemeijer A; Paoloni F; Vignetti M; Fazi P; Meert L; Ramadan SM; Willemze R; de Witte T; Baron F
J Clin Oncol; 2016 Mar; 34(9):972-9. PubMed ID: 26811524
[TBL] [Abstract][Full Text] [Related]
37. Acute leukemia arising from myeloproliferative or myelodysplastic/myeloproliferative neoplasms: A series of 372 patients from the PETHEMA AML registry.
Hernández-Boluda JC; Martínez-Cuadrón D; Pereira A; Rodríguez-Veiga R; Boluda B; Gil C; Casal-Marini S; Serrano J; Martínez-López J; Bergua J; Algarra L; Bernal T; López-Lorenzo JL; Colorado M; López A; Tormo M; Sayas MJ; Trigo F; López-Pavía M; Pérez-Simón JA; Lavilla-Rubira E; Rodríguez-Medina C; Rodríguez-Gutiérrez JI; Sanz-Caballer MA; Montesinos P;
Leuk Res; 2022 Apr; 115():106821. PubMed ID: 35286939
[TBL] [Abstract][Full Text] [Related]
38. Venetoclax in combination with hypomethylating agents or low dose cytarabine for relapsed and refractory acute myeloid leukemia.
Graveno ME; Carulli A; Freyer CW; Mangan BL; Nietupski R; Loren AW; Frey NV; Porter DL; Gill SI; Hexner EO; Luger SM; Martin ME; McCurdy SR; Perl AE; Babushok DV; Pratz KW
Leuk Lymphoma; 2022 Jul; 63(7):1645-1650. PubMed ID: 35259056
[TBL] [Abstract][Full Text] [Related]
39. Clinical experience with venetoclax in patients with newly diagnosed, relapsed, or refractory acute myeloid leukemia.
Fleischmann M; Scholl S; Frietsch JJ; Hilgendorf I; Schrenk K; Hammersen J; Prims F; Thiede C; Hochhaus A; Schnetzke U
J Cancer Res Clin Oncol; 2022 Nov; 148(11):3191-3202. PubMed ID: 35099591
[TBL] [Abstract][Full Text] [Related]
40. Outcomes of patients with relapsed or refractory acute myeloid leukemia: a population-based real-world study.
Brandwein JM; Saini L; Geddes MN; Yusuf D; Liu F; Schwann K; Billawala A; Westcott C; Kurniawan JA; Cheung WY
Am J Blood Res; 2020; 10(4):124-133. PubMed ID: 32923092
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
